AI summary by TwinMind
3 reasons why medications are so expensive in the US - Kiah Williams
TED-Ed
5m 20s
Historical Context & Production Costs
- Frederick Banting transferred insulin patent to University of Toronto for $1 (1921)
- Stated "insulin belonged to the world—not to him"
- Current production costs: <$6 per vial
- US patients pay thousands annually—10x more than other countries
- Some patients reduce prescribed doses due to cost
Research & Development Phase
- R&D costs vary widely by drug
- Failed drug development costs factored into pricing
- Almost every approved drug subsidized by taxes
- Pharmaceutical companies set prices without required justification
Patent Protection & Market Manipulation
- Companies receive patent protection + exclusivity rights
- Patent expiration typically causes price drops
- Companies invest heavily in patent extensions
- Make minor tweaks (dosage, delivery methods)
- Obtain new patents, sue competitors to delay releases
- Humira case study:
- Best-selling autoimmune drug
- Price raised 27x since 2003
- Costs >$96,000/year without insurance
- Insulin market dominated by 3 companies using similar tactics
- Average list prices tripled over 2 decades
Distribution Channels
Retail Channel (most drugs including insulin)
- Pharmaceutical company → wholesalers → pharmacies → patients
Hospital/Clinic Channel
- More expensive, research-intensive therapies for rare conditions
US Healthcare Payment System
- No universal healthcare
- Many Americans use health insurance
- Insured patients: pay portion, pharmacy bills insurer for rest
- Uninsured patients: pay full non-negotiated rates
Pharmacy Benefit Managers (PBMs)
- Companies unique to US market
- Negotiate discounts from manufacturers for insurers
- May pass some discounts to insurers but keep considerable portion
- Limit patient choice
- Sometimes cover expensive branded drugs over cheaper generics for higher profit
Financial Flow Analysis (2018 Insulin Data)
- Manufacturers: 46%
- Wholesalers: 8%
- Pharmacies: 20%
- Insurance companies: 10%
- PBMs: 14%
- 2014-2018 trend: as list prices increased, manufacturer retention decreased
- >50% went to intermediaries
International Comparison
- US: businesses negotiate at various steps
- Other countries: government agencies evaluate benefits, bulk purchase, regulate pricing
- US leads in drug development and profit
- 1 in 4 Americans reported prescription affordability trouble (2019)
Reform Proposals
- Increased regulation in drug pricing, patenting, intermediary profits
- More national health and research funding
- Goal: lower prices while encouraging innovation
- Maintain pharmaceutical company profits through affordability/volume
Recent Developments (2023)
- Largest insulin manufacturer announced substantial list price decrease
- Two other manufacturers followed suit
- Should improve insulin affordability
- System-wide changes needed for comprehensive patient access
